Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

Merete Lund Hetland; Ib Jarle Christensen; Ulrik Tarp; Lene Dreyer; Annette Hansen; Ib Tønder Hansen; Gina Birgitte Kollerup; Louise Linde; Hanne Merete Lindegaard; Uta Engling Poulsen; Annette Schlemmer; Dorte Vendelbo Jensen; Signe Jensen; Gisela Hostenkamp; Mikkel Østergaard; All Departments of Rheumatology in Denmark

doi:10.1002/art.27227

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

Merete Lund Hetland, Ib Jarle Christensen, Ulrik Tarp, Lene Dreyer, Annette Hansen, Ib Tønder Hansen, Gina Birgitte Kollerup, Louise Linde, Hanne Merete Lindegaard, Uta Engling Poulsen, Annette Schlemmer, Dorte Vendelbo Jensen, Signe Jensen, Gisela Hostenkamp, Mikkel Østergaard, All Departments of Rheumatology in Denmark

487 Citations (Scopus)

Abstract

To compare tumor necrosis factor alpha inhibitors directly regarding the rates of treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis (RA), and to identify clinical prognostic factors for response.

Original language	English
Journal	Arthritis & Rheumatism
Volume	62
Issue number	1
Pages (from-to)	22-32
Number of pages	11
ISSN	0004-3591
DOIs	https://doi.org/10.1002/art.27227
Publication status	Published - 1 Jan 2010

Access to Document

10.1002/art.27227

Fingerprint

Dive into the research topics of 'Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry'. Together they form a unique fingerprint.

Cite this

Hetland, M. L., Christensen, I. J., Tarp, U., Dreyer, L., Hansen, A., Hansen, I. T., Kollerup, G. B., Linde, L., Lindegaard, H. M., Poulsen, U. E., Schlemmer, A., Jensen, D. V., Jensen, S., Hostenkamp, G., Østergaard, M., & All Departments of Rheumatology in Denmark (2010). Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis & Rheumatism, 62(1), 22-32. https://doi.org/10.1002/art.27227

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. / Hetland, Merete Lund; Christensen, Ib Jarle; Tarp, Ulrik et al.
In: Arthritis & Rheumatism, Vol. 62, No. 1, 01.01.2010, p. 22-32.

Research output: Contribution to journal › Journal article › Research › peer-review

Hetland, ML, Christensen, IJ, Tarp, U, Dreyer, L , Hansen, A, Hansen, IT, Kollerup, GB, Linde, L, Lindegaard, HM, Poulsen, UE, Schlemmer, A, Jensen, DV, Jensen, S, Hostenkamp, G, Østergaard, M & All Departments of Rheumatology in Denmark 2010, 'Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry', Arthritis & Rheumatism, vol. 62, no. 1, pp. 22-32. https://doi.org/10.1002/art.27227

Hetland ML, Christensen IJ, Tarp U, Dreyer L , Hansen A, Hansen IT et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis & Rheumatism. 2010 Jan 1;62(1):22-32. doi: 10.1002/art.27227

Hetland, Merete Lund ; Christensen, Ib Jarle ; Tarp, Ulrik et al. / Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. In: Arthritis & Rheumatism. 2010 ; Vol. 62, No. 1. pp. 22-32.

@article{56c03c229cb24ef087ff5b0021eff39e,

title = "Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry",

abstract = "To compare tumor necrosis factor alpha inhibitors directly regarding the rates of treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis (RA), and to identify clinical prognostic factors for response.",

author = "Hetland, {Merete Lund} and Christensen, {Ib Jarle} and Ulrik Tarp and Lene Dreyer and Annette Hansen and Hansen, {Ib T{\o}nder} and Kollerup, {Gina Birgitte} and Louise Linde and Lindegaard, {Hanne Merete} and Poulsen, {Uta Engling} and Annette Schlemmer and Jensen, {Dorte Vendelbo} and Signe Jensen and Gisela Hostenkamp and Mikkel {\O}stergaard and {All Departments of Rheumatology in Denmark}",

year = "2010",

month = jan,

day = "1",

doi = "10.1002/art.27227",

language = "English",

volume = "62",

pages = "22--32",

journal = "Arthritis & Rheumatism",

issn = "0004-3591",

publisher = "John/Wiley & Sons, Inc. John/Wiley & Sons Ltd",

number = "1",

}

TY - JOUR

T1 - Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

AU - Hetland, Merete Lund

AU - Christensen, Ib Jarle

AU - Tarp, Ulrik

AU - Dreyer, Lene

AU - Hansen, Annette

AU - Hansen, Ib Tønder

AU - Kollerup, Gina Birgitte

AU - Linde, Louise

AU - Lindegaard, Hanne Merete

AU - Poulsen, Uta Engling

AU - Schlemmer, Annette

AU - Jensen, Dorte Vendelbo

AU - Jensen, Signe

AU - Hostenkamp, Gisela

AU - Østergaard, Mikkel

AU - All Departments of Rheumatology in Denmark

PY - 2010/1/1

Y1 - 2010/1/1

N2 - To compare tumor necrosis factor alpha inhibitors directly regarding the rates of treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis (RA), and to identify clinical prognostic factors for response.

AB - To compare tumor necrosis factor alpha inhibitors directly regarding the rates of treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis (RA), and to identify clinical prognostic factors for response.

U2 - 10.1002/art.27227

DO - 10.1002/art.27227

M3 - Journal article

C2 - 20039405

SN - 0004-3591

VL - 62

SP - 22

EP - 32

JO - Arthritis & Rheumatism

JF - Arthritis & Rheumatism

IS - 1

ER -